Company Overview
Filana Therapeutics, Inc. operates as a clinical stage biotechnology company dedicated to developing pharmaceutical treatments specifically for neurodegenerative diseases. The company's primary focus is on creating drugs that target conditions such as Alzheimer's disease, positioning it within the broader healthcare sector where innovation drives market dynamics. Currently, the entity employs a workforce of 17 individuals to advance its research and development pipeline while maintaining a market capitalization of $80.67M. The company's revenue figure is not disclosed in available financial data, and the absence of reported revenue alongside a market cap of $80.67M indicates that the firm is in a pre-commercialization phase where value is derived from intellectual property and clinical trial progress rather than sales volume. This scale, characterized by a small employee base and a market cap under $100 million, suggests a specialized position in the biotechnology industry where capital allocation is heavily weighted toward clinical milestones rather than immediate profitability.
Financial Health
The company reports a net income of $-90,973,000 and an EBITDA of $-59,154,000 for the trailing twelve months, while revenue and price-to-sales data are not available. The significant gap between the reported net income of $-90,973,000 and the EBITDA of $-59,154,000 reveals a substantial non-operating loss component or significant interest and tax expenses that exacerbate the bottom-line deficit beyond core operational burn. Despite the negative net income and EBITDA, the company maintains a free cash flow of $20.22M, which provides a critical buffer of financial flexibility to fund ongoing clinical trials without immediate external financing. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet generated revenue sufficient to calculate meaningful profitability ratios or that revenue is immaterial relative to expenses. On the balance sheet, the company holds cash reserves of $95.50M against a debt level that is not applicable, resulting in a debt-to-equity ratio that is not applicable, which demonstrates a highly conservative financial structure devoid of leveraged obligations. The current ratio stands at 2.23, indicating that the company possesses 2.23 times the liquid assets necessary to cover its short-term liabilities, thereby ensuring robust short-term liquidity. Return on Equity is reported at -82.7% and Return on Assets at -27.2%, metrics that reveal management is currently deploying capital to achieve future clinical milestones rather than generating immediate shareholder returns.
Valuation Assessment
Trailing P/E and forward P/E ratios are not applicable for Filana Therapeutics, Inc. given the lack of positive earnings, implying that traditional earnings-based valuation models are currently inapplicable to this pre-revenue biotechnology entity. The price-to-book ratio is 1.08, suggesting that the market values the company's equity at a level slightly above its net asset book value, reflecting the intangible value of its clinical pipeline. Since price-to-sales and EV/EBITDA are not applicable or 0.25 respectively, the valuation relies heavily on the price-to-book metric and the specific EV/EBITDA of 0.25, which indicates a market cap significantly lower than the absolute value of enterprise earnings multiples often seen in mature pharmaceutical firms. The stock has traded within a 52-week range with a high of $4.98 and a low of $1.15; based on the provided facts, the specific current trading price is not listed, so the exact percentage deviation from the 52-week high of $4.98 cannot be calculated without the current share price, but the wide range highlights significant intrayear volatility. The beta value is -0.84, a negative coefficient that indicates the stock's price movements are inversely correlated with the broader market, meaning the asset tends to move opposite to the market direction rather than in tandem with it.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are not available in the provided data, preventing a direct comparison of earnings velocity against revenue expansion. Consequently, the company does not pay a dividend, as the dividend yield and payout ratio are not applicable, meaning the entity retains all available cash flow to reinvest into its drug development programs rather than distributing income to shareholders. The absence of a payout ratio of 0.0% confirms that the company prioritizes capital expenditure on its lead therapeutic product candidate, simufilam, over shareholder distributions. The overall growth and income profile for Filana Therapeutics, Inc. is defined by a complete lack of current profitability and dividend generation, with all financial activity directed toward advancing its Phase 3 clinical trial for Alzheimer's disease and securing future market entry.